Vertex buys ViaCyte for $320M, clearing out T1D competition
Stem-Cell Therapy for Type 1 Diabetes Reduced Patient's Insulin Needs by 91%
Vertex reports positive results for first patient in Type 1 diabetes trial - The Boston Globe
Vertex upbeat on 1st stem cell therapy for diabetes trial participant - The Niche
Diabetes space continues to run hot with Vertex/ViaCyte deal - MM+M
Vertex Moves Full Steam Ahead on Type 1 Diabetes Drug Trial With FDA's OK | BioSpace
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff
Vertex to acquire rival diabetes drug developer ViaCyte
Vertex builds up pipeline of type 1 diabetes cell therapies with $320M buyout - MedCity News
Vertex Pharmaceuticals am 52-Wochenhoch – Studie für Stammzellentherapie gegen Diabetes-Typ-1 wird fortgesetzt!
JDRF Report: Vertex Has a New Horizon: Curing Type 1 Diabetes
Vertex to Acquire ViaCyte for $320M, Growing Diabetes Cell Therapy Pipeline
Vertex – type 1 diabetes vs stem cell therapy - The Boar
Vertex Releases New Data on Potential Cure for Type 1 Diabetes
Vertex Acquires Semma Therapeutics Diabetes Research Firm
Frontiers | Stem Cell-Based Clinical Trials for Diabetes Mellitus
Vertex Type 1 Diabetes Research Stirs Hope for Stem Cell-Based 'Cure'
Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte
Vertex: Trial of New Type 1 Diabetes Cell Therapy Put on Hold - DSM
Clinical Trial for Novel Investigational Treatment of Type 1 Diabetes Open for Enrollment in Miami - World Stem Cell Summit
Vertex: Impressive early results for potentially curative diabetes cell therapy
Vertex spends nearly $1bn on Semma's unproven diabetes cell tech | Evaluate
Vertex to buy Semma Therapeutics for $950m in cash
Vertex to acquire ViaCyte, targeting type 1 diabetes
Vertex eyes type 1 diabetes cure with biotech acquisition - PMLiVE
